Axcella Announces Upcoming Presentations at NASH-TAG 2021
-
Abstract #22: “Mechanistic insights into AXA1125, a novel endogenous metabolic modulator composition, targeting multiple
NASH drivers”
-
Abstract #33: Distinguished Abstract and Poster Award to be presented by
Nadege T. Gunn , M.D., Lead Physician Investigator atPinnacle Clinical Research inAustin, TX and Adjunct Assistant Professor atTexas A&M University College of Medicine . “Safety, tolerability, and biological activity of AXA1125 and AXA1957 in a prospective 16-week randomized, placebo-controlled study in subjects with NAFLD with and without type 2 diabetes”
- Abstract #34: “Biological activity of AXA1125 and AXA1957 on glucose, insulin, HOMA-IR, and HbA1c and measures of liver fat and fibroinflammation in a prospective 16-week randomized, placebo-controlled study in subjects with NAFLD and type 2 diabetes”
About Endogenous Metabolic Modulators (EMMs)
EMMs are a broad family of molecules, including amino acids, that regulate human metabolism. Axcella is developing a range of novel product candidates that are comprised of multiple EMMs engineered in distinct combinations and ratios to simultaneously impact multiple metabolic pathways to modify the root causes of various complex diseases and improve health.
Internet Posting of Information
Axcella uses its website, www.axcellahealth.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the company’s website in the “Investors and News” section. Accordingly, investors should monitor this portion of the company’s website, in addition to following its press releases,
About Axcella
Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (
View source version on businesswire.com: https://www.businesswire.com/news/home/20210225005043/en/
jfredette@axcellahealth.com
857.320.2236
Source: Axcella